EMA/748663/2013
EMEA/H/C/1226

Public statement

Clopidogrel Teva Pharma B.V.

Withdrawal of the marketing authorisation in the European Union

On 21 October 2014 the European Commission withdrew the marketing authorisation for Clopidogrel Teva Pharma B.V. (clopidogrel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva Pharma B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Clopidogrel Teva Pharma B.V. was granted marketing authorisation in the EU on 16 June 2011 for the prevention of atherothrombotic events (problems caused by blood clots and hardening of the arteries). The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU.

Clopidogrel Teva Pharma B.V. is a generic medicine of Plavix. There are other generic medicinal products of Plavix authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Clopidogrel Teva Pharma B.V. will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact